Welcome to our dedicated page for KESTRA MED TECHNOLOGIES news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KESTRA MED TECHNOLOGIES stock.
Kestra Medical Technologies reports developments as a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular disease. Its updates center on the Cardiac Recovery System platform and the ASSURE WCD, a wearable cardioverter defibrillator used for patients at elevated risk of sudden cardiac arrest.
Recurring news includes fiscal results and revenue guidance, clinical data from the ASSURE WCD post-approval study, product and algorithm updates, healthcare conference presentations, and collaborations aimed at expanding diagnostic insight during cardiac recovery.
Kestra Medical Technologies (Nasdaq: KMTS) entered a five-year term loan facility with funds managed by Pharmakon Advisors, providing up to $200 million in non-dilutive financing. The structure includes a $75 million tranche funded at closing (used in part to retire a $45 million term loan and pay fees), a $25 million tranche available at Kestra’s option through July 2027, and a $50 million tranche available through June 2028, subject to achieving $150 million in trailing 12-month revenue. An additional $50 million uncommitted tranche for acquisitions is available subject to Pharmakon’s consent.
The facility features 48 months of interest-only payments, extendable by 12 months upon a revenue milestone, with interest at 3‑month SOFR + 5.5%, subject to a 3.25% SOFR floor. According to Kestra, cash, cash equivalents and investments were $262 million as of April 30, 2026, and total liquidity including unused committed availability is about $357 million. Armentum Partners acted as financial advisor.
Kestra Medical Technologies (Nasdaq: KMTS) reported fiscal 4Q26 revenue of $28.6 million, up 66% year over year, and FY26 revenue of $95.1 million, up 59% versus FY25. Fourth-quarter gross margin improved to 54.8% from 44.3%, while FY26 gross margin rose to 51.4% from 40.5%. FY27 revenue is guided to $137 million, implying 44% growth.
According to Kestra, 4Q26 ASSURE® system prescriptions increased 63% to 6,357, and FY26 prescriptions rose 57% to 20,720. 4Q26 GAAP net loss narrowed to $38.8 million, but FY26 GAAP net loss widened to $131.6 million. Adjusted EBITDA loss was $26.7 million in 4Q26 and $87.0 million for FY26. Cash, cash equivalents and investments totaled $262.2 million, with net cash used in operating activities reduced to $18.7 million for the year.
Kestra Medical Technologies (Nasdaq: KMTS) will report fourth quarter fiscal 2026 financial results after the market closes on Tuesday, July 14.
Management will host a conference call at 4:30 p.m. Eastern Time, with a live and archived webcast available in the investor relations website’s Events section.
Kestra Medical Technologies (Nasdaq: KMTS) will present at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026 at 2:20 p.m. PT.
Investors and interested parties can watch a live webcast and access a replay via the Kestra investor relations website.
Kestra (Nasdaq: KMTS) will exhibit at Heart Rhythm 2026 in Chicago April 23–26 and showcase its Cardiac Recovery System and ASSURE WCD platform.
The company highlights ACE-PAS, the largest prospective wearable defibrillator study, and is launching an FDA-approved ASSURE WCD algorithm update. Visit Booth 2119 to review clinical data and product demos.
Kestra Medical Technologies (NASDAQ: KMTS) announced on April 9, 2026 that it was named a 2026 USA TODAY Top Workplaces award winner.
The recognition is based on confidential employee feedback collected via an Energage survey measuring engagement, alignment, and organizational performance, highlighting company culture and team trust.
Kestra Medical Technologies (Nasdaq: KMTS) was named a finalist for the 2026 GeekWire Awards “Deal of the Year” for its successful 2025 initial public offering. The recognition cites impactful transactions and highlights Kestra’s expanding Pacific Northwest presence and commercial growth of its Cardiac Recovery System®.
Community voting runs through April 16, 2026, with winners announced at the GeekWire Awards ceremony on May 7, 2026 in Seattle.
Kestra Medical Technologies (Nasdaq: KMTS) reported Q3 FY2026 results for the period ended January 31, 2026, with $24.6M revenue (+63% YoY) and gross margin expanding to 52.6% from 43.4%. The company raised FY26 revenue guidance to $93M (up 55% YoY) and reported $291M cash.
Operational highlights included 5,462 ASSURE prescriptions (+58%), an equity offering closed Dec 4, 2025, and adjusted EBITDA loss of $21.2M.
Kestra Medical Technologies (Nasdaq: KMTS) will report third quarter fiscal 2026 results on Tuesday, March 17, 2026 with a conference call at 4:30 p.m. ET. A live and archived webcast will be available in the investor relations Events section; participants are asked to register 10 minutes early.
Kestra Medical Technologies (Nasdaq: KMTS) announced a strategic collaboration and exclusive license/co-development with Biobeat to integrate Biobeat’s FDA-cleared, cuffless 24-hour ambulatory blood pressure monitoring (ABPM) into the ASSURE Wearable Cardioverter Defibrillator (WCD) ecosystem.
The agreement includes a $5 million equity investment in Biobeat’s Series B and aims to provide continuous, noninvasive blood pressure data to support at-home cardiac recovery. Kestra cited its ACE-PAS study where 72% of patients were hypertensive, underscoring the partnership’s clinical relevance for guideline-directed medical therapy optimization.